help button home button Endocrine Society Endocrine Reviews
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Endocrine Reviews, doi:10.1210/er.2009-0004
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints, Permissions and Rights
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Guo, T.
Right arrow Articles by Hebrok, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Guo, T.
Right arrow Articles by Hebrok, M.
Endocrine Reviews 30 (3): 214-227
Copyright © 2009 by The Endocrine Society

Stem Cells to Pancreatic β-Cells: New Sources for Diabetes Cell Therapy

Tingxia Guo and Matthias Hebrok

Diabetes Center, Department of Medicine, University of California, San Francisco, San Francisco, California 94143

Correspondence: Address all correspondence and requests for reprints to: Matthias Hebrok, Diabetes Center, Department of Medicine, University of California, San Francisco, San Francisco, California 94143. E-mail: mhebrok{at}diabetes.ucsf.edu

The number of patients worldwide suffering from the chronic disease diabetes mellitus is growing at an alarming rate. Insulin-secreting β-cells in the islet of Langerhans are damaged to different extents in diabetic patients, either through an autoimmune reaction present in type 1 diabetic patients or through inherent changes within β-cells that affect their function in patients suffering from type 2 diabetes. Cell replacement strategies via islet transplantation offer potential therapeutic options for diabetic patients. However, the discrepancy between the limited number of donor islets and the high number of patients who could benefit from such a treatment reflects the dire need for renewable sources of high-quality β-cells. Human embryonic stem cells (hESCs) are capable of self-renewal and can differentiate into components of all three germ layers, including all pancreatic lineages. The ability to differentiate hESCs into β-cells highlights a promising strategy to meet the shortage of β-cells. Here, we review the different approaches that have been used to direct differentiation of hESCs into pancreatic and β-cells. We will focus on recent progress in the understanding of signaling pathways and transcription factors during embryonic pancreas development and how this knowledge has helped to improve the methodology for high-efficiency β-cell differentiation in vitro.




This article has been cited by other articles:


Home page
J Mol Cell BiolHome page
J. Cai, C. Yu, Y. Liu, S. Chen, Y. Guo, J. Yong, W. Lu, M. Ding, and H. Deng
Generation of Homogeneous PDX1+ Pancreatic Progenitors from Human ES Cell-derived Endoderm Cells
J Mol Cell Biol, February 1, 2010; 2(1): 50 - 60.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2009 by The Endocrine Society